mutagen sensit patient head neck cancer biolog marker risk multipl primari malign eighty-four patient head neck cancer vitro sensit mutagen develop multipl primari malign mutagen sensit lymphocyt vitro bleomycin-induc chromosom break cell mutagen-hypersensit patient ie break cell like multipl primari cancer patient sensit equal break cell rel risk confid limit relationship independ age sex site treatment first primari cancer tobacco alcohol exposur sensit bleomycin-induc chromosom damag serv indic genet suscept primari malign patient head neck cancer 